Latest Breaking News On - Manag care spec - Page 4 : comparemela.com

Medicare Coverage of Buprenorphine-Naloxone Film Surrounding Generic Entry

Medicare plans are replacing brand-name buprenorphine-naloxone film with its generic equivalents, resulting in a decrease in out-of-pocket cost faced by enrollees with opioid use disorder.

New yorkUnited statesPuerto ricoChao zhangPharmacy networkHealth aff millwoodDepartment of psychiatryDepartment of population health sciencesDivision of infectious diseasePublic healthValue healthRural healthNational institute on drug abusePr health sciDepartment of medicineNational drug codes ndcs

Non–Face-to-Face Care Management and Service Utilization in Patients With Diabetes

CMS began reimbursement for non–face-to-face chronic care management in 2015, and results from Louisiana show that it increases outpatient visits but decreases inpatient and emergency department encounters.

United statesFrance generalNew orleansPatricia dominickBurgess jf jrCharles stoeckerCathy gloverResearch action for health networkPcornet clinical research networkDepartment of medicineHealth services researchPennington biomedical research centerTulane universityOchsner health systemResearch action for health network reachnetDepartment of health

Elevating the Therapeutic Relationship: The Future of Pharmacists in Outpatient Mental Health Services

Pharmacists working with patients with mental health conditions are able to optimize medication use and improve adherence.

United statesInnov clin neurosciCarl rogersAshley sturmElise mooreHealth resources services administrationUniversity of minnesota college pharmacyNational alliance of mental illnessJ health syst pharmHealth workforce shortage areas dashboardNational alliance on mental illnessA mental health testTnj healthPharmacist role in public healthAust new zealand healthMental health america

F Hoffmann-La Roche Ltd: Positive Phase III results for Roche s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis

F Hoffmann-La Roche Ltd: Positive Phase III results for Roche s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesKirti pandeyNathalie altermattSabine borngrSileia urechLevi garrawayBirgit masjostBruno eschliKarsten kleineGerard tobinLoren kalmRoche group media relationsHead of global product developmentRoche groupChief medical officerGlobal product

Positive Phase III Results for Genentech s Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis

–– Phase III OCARINA II trial met primary and secondary endpoints–– Ocrevus 10-minute injection has the potential to further improve the treatment experience and expand Ocrevus® usage in MS centers with IV capacity limitations or without IV infrastructure–– Ocrevus remains the first and only therapy approved for bot.

South san franciscoUnited statesLoren kalmLevi garrawayMichelle mccourtJo dulayBruno eschliRoche groupGlobal product developmentGlobal productHalozyme therapeutic enhanzeImportant safetyMultifocal leukoencephalopathyOcrevus pregnancyPrescribing informationManag care spec